News
Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services ...
Real world data that harnesses deidentified health records is a multi-billion-dollar industry. But what is the value of a ...
23andMe filed for for Chapter 11 bankruptcy protection in March. Last month, Regeneron announced that it would purchase most of 23andMe's assets for $256 million, but it was outbid.
23andMe co-founder and CEO Anne Wokcicki won back control of the genetic-test company after a prolonged bankruptcy fight that at one point was won by Regeneron.
Regeneron Pharmaceuticals (REGN) exits buyout race for 23andMe as Anne Wojcicki's TTAM Research offers a superior $305M bid. Read more here.
Hosted on MSN2mon
Regeneron CEO on 23andMe bid: Trying to balance individual ... - MSN
Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology ...
23andMe struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, setting the stage for new bids. This drug exec doesn't do 'mediocre ...
In response to questions about the lawsuit, Regeneron, which is based in Tarrytown in New York's lower Hudson Valley, noted in a statement that the 23andMe bankruptcy auction has been reopened and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results